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Abstract
Introduction: Several reports have shown marked heterogeneity of antibiotic pharmacokinetics (PK) in patients
admitted to ICUs, which might potentially affect outcomes. Therefore, the pharmacodynamic (PD) parameter of the
efficacy of b-lactam antibiotics, that is, the time that its concentration is above the bacteria minimal inhibitory
concentration (T > MIC), cannot be safely extrapolated from data derived from the PK of healthy volunteers.
Methods: We performed a full review of published studies addressing the PK of intravenous b-lactam antibiotics
given to infected ICU patients. Study selection comprised a comprehensive bibliographic search of the PubMed
database and bibliographic references in relevant reviews from January 1966 to December 2010. We selected only
English-language articles reporting studies addressing b-lactam antibiotics that had been described in at least five
previously published studies. Studies of the PK of patients undergoing renal replacement therapy were excluded.
Results: A total of 57 studies addressing six different b-lactam antibiotics (meropenem, imipenem, piperacillin,
cefpirome, cefepime and ceftazidime) were selected. Significant PK heterogeneity was noted, with a broad, more
than twofold variation both of volume of distribution and of drug clearance (Cl). The correlation of antibiotic Cl
with creatinine clearance was usually reported. Consequently, in ICU patients, b-lactam antibiotic half-life and T >
MIC were virtually unpredictable, especially in those patients with normal renal function. A better PD profile was
usually obtained by prolonged or even continuous infusion. Tissue penetration was also found to be compromised
in critically ill patients with septic shock.
Conclusions: The PK of b-lactam antibiotics are heterogeneous and largely unpredictable in ICU patients.
Consequently, the dosing of antibiotics should be supported by PK concepts, including data derived from studies
of the PK of ICU patients and therapeutic drug monitoring.
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Introduction
Infection and sepsis, whether community- or hospital-
acquired, are important causes of morbidity and mortal-
ity in ICU patients [1,2]. Despite all of the research, sep-
sis therapy continues to depend on supportive
management of the different organ dysfunctions and
failures and on specific therapy for infection with timely
and appropriate antibiotics and/or focus control.
The b-lactam antibiotics, because of their large anti-
microbial spectrum and low toxicity, are among the
first-line therapies for critically ill patients, especially
when a Gram-negative infection is suspected. However,
the efficacy of antibiotics is not easily evaluated, since
the clinical response is usually unnoticeable before 48
hours of therapy [3]. Moreover, the unavailability of rou-
tine therapeutic drug monitoring for the great majority
of these drugs makes it difficult to distinguish clinical
failure due to underdosing from lack of in vivo organism
susceptibility.
Considerable evidence demonstrates that free drug
time above bacteria minimal inhibitory concentration (f
T > MIC) is the measure of drug exposure most closely
linked to the ability of b-lactam antibiotics to kill the
target bacteria [4]. T > MIC is dependent on the half-
life (T1/2)o fb-lactam antibiotics and their serum
concentration.
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the dose delivered, its bioavailability and its volume of
distribution (Vd). Vd is a mathematical construct and
refers to the size of a compartment necessary to account
for the total amount of the drug, assuming that its con-
centration in the whole body is equal to that measured
in plasma. Drugs that distribute essentially in the extra-
cellular fluid (mainly hydrophilic) have low Vd, whilst
drugs that have rapid cellular uptake (lipophilic) have
high Vd[5,6].
Both Vd and drug clearance (Cl) may be increased in
ICU patients [7]. Therapeutic procedures, notably
large-volume and blood products infusions, positive
pressure ventilation, surgical procedures, capillary leak
and reduction in albumin serum concentration all con-
tribute to alter the concentration-time relationship of
many drugs. A rise in the Vd, although it reduces drug
concentration, might proportionally increase T1/2,
since T1/2 = Vd/(Cl × 0.693) [7]. On the contrary, a
high Cl may reduce the exposure of antibiotics to bac-
teria (Figure 1).
Renal Cl may be increased in septic patients because
of increased renal blood flow. This has recently been
shown to be a common finding in ICU patients, particu-
larly surgical and trauma patients [8] but also septic
medical patients [9]. Besides, in the study by Baptista et
al. [9], the authors showed that commonly used formu-
las used to calculate glomerular filtration rate usually
underestimate creatinine (Cr) Cl. Consequently, these
authors recommended direct Cr Cl measurement.
Moreover in ICU patients, maldistribution of blood
flow in the microcirculation [10], namely, in patients in
septic shock, may further decrease the drug concentra-
tion in the infected tissue [11]. These pharmacokinetic
(PK) changes are sometimes influenced by the clinical
course of the infection itself [12]. Consequently, PK
parameters measured in healthy volunteers may not cor-
rectly predict concentrations in septic ICU patients, par-
ticularly early in the course of a severe infection [13,14].
Ideally, individualized dosing strategies should account
for the altered PK and pathogen susceptibility in each
patient. Despite the fact that some studies addressed
this issue, this information had not yet been aggregated.
Furthermore, b-lactam antibiotic PK are rarely analysed
outside clinical trials. Therefore, we performed a sys-
tematic review of studies that addressed the PK para-
meters of b-lactam antibiotics in ICU patients to assess
the relationship between dose and schedule of b-lactam
antibiotics and their adequacy according to pharmaco-
dynamic (PD) end points. We also reviewed studies
assessing the concentrations of b-lactam antibiotics in
different tissues. Our primary intention was to aggregate
PK information in this particular population and to con-
tribute to the design of individualized dosing regimens
of these drugs.
We also included studies that involved the develop-
ment of PD models using PK of ICU patients and bac-
terial MICs. These techniques allow the calculation of
the presumed T > MIC and therefore the percentage of
patients in which the antibiotic will achieve its PD
Figure 1 ICU patients present pharmacokinetic changes of antibiotics that may alter bacterial exposure. Concentration-time curve of
antibiotics in healthy volunteers (left panel). A large volume of distribution (Vd) (middle panel) is often present in ICU patients, leading to
decreased maximum concentration (Cmax) but a longer half-life (T1/2) and eventually higher time that the antibiotic concentration is above the
bacteria minimum inhibitory concentration (T > MIC). The antibiotic area under the concentration time curve (AUC) remains virtually the same.
An increase in drug clearance (Cl) (right) is associated with decreases in AUC, T1/2 and T > MIC. Straight dotted lines-bacteria minimum inhibitory
concentration.
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ment (PTA) [15,16]. The cumulative fraction of
response (CFR) is calculated by multiplying the PTA
obtained for each MIC by the MIC distribution accord-
ing to a microbiological database [16].
Materials and methods
The data for this review were identified by a search of
PubMed (January 1966 to December 2010) as well as
bibliographic references from relevant articles, including
reviews on this subject and all selected studies. The
search terms used were ‘antibiotic’ or ‘carbapenem’ or
‘penicillins’ or ‘cephalosporins’,a n d‘intensive care’ or
‘critically ill’ or ‘critical care’ or ‘severe sepsis’ or ‘septic
shock’,a n d‘pharmacokinetics’ or ‘pharmacodynamics’.
All relevant studies in the English-language literature
that described antibiotic PK in critically ill patients were
assessed (Figure 2).
234 Articles evaluated
50 not evaluating Pharmacokinetics
10 Pharmacokinetic models
1 non iv route
19 not β-Lactams
21 elective prophylaxis use
15 children only
3 non humans
15 non critically ill patients
2 single patient Pharmacokinetics
7 non english language
35 Use of Renal Replacement Therapy
71 Articles further assessed
15 articles selected from reference
articles bibliography
Antibiotics with less than 5 
published studies (14):
Cefoxitin 1
Apalcillin 1
Flucloxacillin 1
Cefmenoxime 1
Cefixime 1
Co-amoxiclav 1
Ertapenem 2
Temoxicillin 1
Ceftriaxone 3
Mezlocillin 1
Cefodizime 1
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Figure 2 Flow diagram illustrating the selection of studies included in this review.
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intravenously to infected patients were selected. Studies
referring to prophylactic antibiotics or to PK in patients
under any type of renal replacement therapy were
excluded. In fact, these studies are mainly directed to
the measurement of Cl during renal replacement ther-
apy to determine the ideal antibiotic dose and therefore
are not easily compared with studies addressing the
intrinsic PK of ICU patients. Furthermore, a full revision
of those studies has recently been published [17].
For the purpose of our systematic review, we analysed
only studies of antibiotics with at least five published
references. This threshold of five referenced studies was
arbitrarily chosen so that we could derive more repre-
sentative and consistent data on the PK of each antibio-
tic. The weighted mean of the Vd was calculated so that
we could present a graphic representation of each ana-
lysed antibiotic (Figure 3).
Results
A total of 57 studies assessing an aggregate of six differ-
ent b-lactam antibiotics were selected.
Carbapenem
Meropenem
Several studies have addressed meropenem PK in ICU
septic patients. High Vd and Cl have usually been
reported, as well as a low binding fraction: < 10% [18].
Consequently, a large heterogeneity of PK parameters
was found, exceeding a twofold variation (Table 1 and
Figure 3). The larger reported Vd, a mean of 34.4 L, was
noted on the second day of therapy in eight ventilator-
associated pneumonia (VAP) patients [19] with a mean
body weight of 73 kg. In a Thai VAP population (N =9 )
with a lower mean body weight (only 54.2 kg), the mean
Vd was 6.0 L despite also being measured after 48 hours
of therapy with meropenem [20]. This supports the
hypothesis of a potential relationship between body
weight and Vd.
Meropenem Cl ranged from a mean of 4.7 L/hour to a
mean of 15.4 L/hour and was generally found to be clo-
sely correlated to Cr Cl. In fact, in patients with severe
sepsis, the six patients with the lower Cr Cl (< 50 mL/
minute) had the higher T > MIC and area under the
concentration time curve (AUC) (230.2 mg × hour/L vs.
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Figure 3 Heterogeneity of volume of distribution in litres of b-lactam antibiotics in ICU patients. Open circles: volume of distribution in
healthy volunteers [44,51,89-92]; filled squares: weighted means of volume of distribution in the studies; straight lines: ranges of the means of
volume of distribution in the studies.
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Page 4 of 17Table 1 Pharmacokinetic parameters of b-lactam antibiotics
a
PK
parameters
Study
Antibiotic drug
classes and drugs
Vd, L Cl, L/hour T1/2, hours Patient demographics Study types [93] References
Carbapenems
Meropenem 21.2 ± 4.7
b 11.3 ± 4
b 1.4 ± 0.4
b N =1 1
Age 63.1 years [23 to
81]
Mild to severe
intraabdominal sepsis
Descriptive Lovering et al., 1995
[22]
Meropenem 26.6 ± 3.2
c 9.4 ± 1.2
c 2.0 N =1 5
Age 55.3 ± 14.3 years
Severe sepsis
Randomized, controlled
cross-over
Thalhammer et al., 1999
[27]
Meropenem 34.4 ± 15.9 11 ± 4.3 0.4 ± 0.12 N =8
Age 55 ± 8 years
VAP
Descriptive de Stoppelaar et al.,
2000 [19]
Meropenem 19.7 ± 5 7.3 ± 3.1 3.1 ± 1.5 N =1 4
Age 73.3 ± 8.1 years
Severe sepsis
Descriptive Kitzes-Cohen et al.,
2002 [21]
Meropenem 16.0 ± 3.7
d 8.5 ± 3.2
d 1.4 ± 0.6
d N =9
Age 39.6 ± 15.7 years
VAP
Not randomized,
controlled cross-over
Jaruratanasirikul et al.,
2005 [20]
Imipenem Imipenem
17.7 ± 4
Imipenem
7.0 ± 2.5
Imipenem
2 ± 0.3
Imipenem
N =1 0
Age 65 ± 19 years
Randomized, parallel
controlled
Novelli et al., 2005 [29]
Meropenem Meropenem
27.1 ± 7.7
Meropenem
11.5 ± 3.1
Meropenem
2.1 ± 0.5
Meropenem
N =1 0
Age 67 ± 19 years
Severe sepsis
Meropenem 23.8 ± 4.9 6.7 ± 4.2 3.7 ± 1.9 N =6
Age 65.7 ± 11.2 years
Peritonitis
Descriptive Karjagin et al., 2008 [25]
Meropenem 22.7 13.6 ± 1.3 NR N =1 0
Age range 48 to 63
years
Severe sepsis
Randomized, parallel
controlled
Roberts et al., 2009 [24]
Meropenem Meropenem
30.1
[21.7 to 53.9]
e
Meropenem
8 [5 to 10.99
e
Meropenem
2.1
[1.7 to 3.4]
Meropenem
N =1 6
Cross-sectional Taccone et al., 2010 [23]
Piperacillin Piperacillin
26.6
[20.3 to 30.1]
e
Piperacillin
8.4
[5.5 to 18.1]
e
Piperacillin
2.6
[1.5 to 3.8]
Piperacillin
N =2 7
Ceftazidime Ceftazidime
33.6
[25.2 to 49.7]
e
Ceftazidime
3.8
[2.5 to 5.5]
e
Ceftazidime
5.8
[4.1 to 7.4]
Ceftazidime
N =1 8
Cefepime Cefepime
25.2
[23.1 to 30.8]
e
Cefepime
5.5
[4.6 to 8.4]
e
Cefepime
3.4
[2.3 to 5.3]
Cefepime
N =1 9
All patients: median age
63 years
Severe sepsis or septic
shock
Imipenem 31.4 ± 11.7 14.4 ± 4.5 1.6 ± 1.3 N =1 0
Age 44 ± 12.2 years
Severe sepsis
Descriptive McKindley et al., 1996
[34]
Imipenem 18.5 6.3 ± 0.8 2.0 N =6
Age 63.5 ± 16.7 years
Severe sepsis
Not randomized,
parallel, controlled
Tegeder et al., 2002 [32]
Imipenem 45.5 ± 47.2 12.1 ± 12.0 2.9 ± 1.7 N =5 0
Age 45.2 ± 17 years
Presumed Gram-
negative sepsis
Cross-sectional Belzberg et al., 2004
[28]
Gonçalves-Pereira and Póvoa Critical Care 2011, 15:R206
http://ccforum.com/content/15/5/R206
Page 5 of 17Table 1 Pharmacokinetic parameters of b?β?-lactam antibiotics
a (Continued)
Imipenem 12.2 ± 9.9
f 12.3 ± 4.2 NR N =2 0
Age 60.5 years
VAP
Randomized, parallel,
controlled
Sakka et al., 2007 [31]
Imipenem 27.2 ± 6.5 13.3 ± 5.2 1.4 ± 0.2 N =6
Age 53.3 ± 19.9 years
Severe sepsis
Not randomized,
parallel, controlled
Dahyot et al., 2008 [33]
Imipenem 16.7 ± 5.3
g 8.7 ± 5.3
g 1.5 ± 0.7
g N =9
Age 63.3 ± 14.9 years
VAP
Not randomized,
controlled, cross-over
Jaruratanasirikul and
Sudsai, 2009 [30]
Penicillins
Piperacillin 25.0 ± 17.2 23.8 ± 17.2 1.5 ± 2.1 N =1 1
Age 43.6 ± 15.9 years
Surgical patients
Descriptive Shikuma et al., 1990
[36]
Piperacillin 19.5 ± 3.4
b 8.4 ± 1.4
b 1.8 ± 0.3
b N =1 0
Age 37.7 ± 2.8 years
Burn patients
Descriptive Bourget et al., 1996 [38]
Piperacillin 40.7 ± 8.7 8.2 ± 2 4.1 ± 1.3 N =6
Age 64 ± 7 years
Septic shock
Not randomized,
parallel, controlled
Joukhadar et al., 2001
[44]
Piperacillin 34.6 ± 6.8
c 11.8 ± 4.3
c 2.4 ± 1.2
c N =7
Age range 45 to 76
years
Severe sepsis
Not randomized,
controlled, cross-over
Langgartner et al., 2007
[39]
Piperacillin 11.7
f 17.2 0.4 N =1 3
Age 37.5 ± 19.4 years
Severe sepsis
Randomized, parallel,
controlled
Roberts et al., 2009 [45]
Cephalosporins
Cefpirome 23.6 ± 8.0 8.0 ± 3.0 2.2 ± 0.5 N =9
Age 31 years [19 to 53]
Severe sepsis
Not randomized,
parallel, controlled
Jacolot et al., 1999 [47]
Cefpirome 26.4 ± 7.9 8.8 ± 3.4 3.1 ± 1.2 N =1 2
Age 41.2 ± 19 years
Severe sepsis
Descriptive Lipman et al., 2001 [48]
Cefpirome 25.9 ± 7.1 4.5 ± 0.7 3.3 ± 0.5 N =1 2
Age 67.2 ± 8.1 years
Severe sepsis or septic
shock
Not randomized,
parallel, controlled
Joukhadar et al., 2002
[52]
Cefpirome 21.9 ± 4.5 4.8 ± 1.6 3.1 ± 0.9 N =1 1
Age 66 ± 8 years
Severe sepsis
Not randomized,
parallel, controlled
Sauermann et al., 2005
[51]
Cefepime 32.6 ± 17.5 7.5 ± 3.1 3.5 ± 1.1 N =7
Age 73.7 ± 4.9 years
Severe sepsis
Descriptive Kieft et al., 1993 [53]
Cefepime 21.8 ± 5.1 7.6 ± 2.0 3 ± 1.2 N = 13
Age 55 years
Severe sepsis
Descriptive Lipman et al., 1999 [56]
Cefepime 36.1 ± 11.8 8.8 ± 2.4 2.8 ± 0.6 N =1 2
Age 41 ± 13 years
Burn patients
Descriptive Bonapace et al., 1999
[57]
Cefepime 26.0
b 9.1 ± 1.5
b 2.5 ± 0.6
b N =6
Age 39.8 ± 11.3 years
Burn patients
Descriptive Sampol et al., 2000 [61]
Cefepime Cefepime 19.6 Cefepime 7.1
± 3.6
Cefepime 2.9
± 3.2
Cefepime
N =1 3
Age 48.2 ± 21.2 years
Cross-sectional Conil et al., 2007 [54]
Ceftazidime Ceftazidime
28.8
Ceftazidime
7.5 ± 3.8
Ceftazidime
3.1 ± 2.1
Ceftazidime
N =1 7
Age 62.9 ± 22.4 years
Burn patients
Cefepime 28.7 ± 13.3
d 9.1 ± 5.6
d 4.3 ± 4.2 N =2 1
Age 55.1 years (median)
Nosocomial pneumonia
Cross-sectional Chapuis et al., 2010 [55]
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Page 6 of 17119.4 mg × hour/L; P = 0.001), despite a reduction in
the dose administered, from 1 g every 8 h (tid) to 1 g
every 12 h (bid) [21].
One study addressed the variability of individual mer-
openem PK between the first and fourth days of therapy
in 11 surgical patients [22]. Despite an increase in Cr Cl
from a mean of 63.9 to 79.1 mL/minute during the
study period, meropenem Vd,C la n dA U Cr e m a i n
unchanged. Nevertheless, in another study, by Taccone
et al. [23], predefined targets were reached in only 75%
of severe sepsis and septic shock patients after the first
dose of 1 g of meropenem (Table 2), despite the inclu-
sion of patients with acute renal failure (22%) who did
not receive renal replacement therapy. These authors
concluded that PK changes induced by sepsis were lar-
gely unpredictable and that none of the evaluated clini-
cal parameters were predictive of PK adequacy: namely,
age, severity, presence of shock, use of vasopressors and
mechanical ventilation. Also, Roberts et al.[ 2 4 ]s h o w e d
that the Vd in patients with severe sepsis had great
variability, both in the same patient (especially the cen-
tral compartment: roughly 45%) and in different patients
(nearly 27%). In their study, despite the fact that all
patients had a serum Cr < 1.36 mg/dL, the meropenem
Cl variability (in the same patient and between patients)
still ranged between 10% and 20%.
The time of infusion of meropenem has also been
shown to influence its T > MIC. In a cross-over study
of nine Thai VAP patients [20], after 48 hours of ther-
apy, 1 g of meropenem tid in 30-minute infusions pro-
vided an adequate T > MIC in 74.7% of the patients, for
a MIC of 1 mg/L. However, with a MIC of 16 mg/L,
only the meropenem regimen of 2 g tid given in an
extended infusion (two hours) led to a T > MIC > 40%
[20].
M e r o p e n e mt i s s u eP Kh a v eb e e ne v a l u a t e db ym i c r o -
dialysis in several studies (Table 3). The tissue-to-plasma
meropenem mean ratio on the first day of antibiotic
therapy was found to be 0.74 in the peritoneum [25]
and 0.44 in subcutaneous fat [24]. The meropenem CFR
was calculated for the 10 patients for whom serum
levels were measured in this study according to the
Mystic microbiological database [26]. The CFRs were
100% for Enterobacteriaceae and 40.6% for Pseudomonas
Table 1 Pharmacokinetic parameters of b?β?-lactam antibiotics
a (Continued)
Ceftazidime 24.5 7.5 2.1 N =1 6
Age range 18 to 70
years
Pseudomonas infection
Descriptive Rondanelli et al., 1986
[64]
Ceftazidime 49.3 ± 18.2
e 15.5 ± 2.5
e 1.8 ± 0.5
e N =5
Age 52.3 years [21 to
69]
VAP
Not randomized,
controlled, cross-over
Langer et al., 1991 [76]
Ceftazidime 29.5 ± 8.7 4.2 ± 1.9 6.1 ± 2.5 N =1 2
Age 60 ± 13 years
VAP
Not randomized,
controlled, cross-over
Bressolle et al., 1992
[77]
Ceftazidime 18.9 ± 9
c 5.1
c 3.5 ± 1.6
c N =1 2
Age 57 ± 12 years
Suspected Gram-
negative sepsis
Not randomized,
controlled, cross-over
Benko et al., 1996 [67]
Ceftazidime 15.0 ± 4.3 5.2 ± 2.2 1.3 ± 1.2 N =1 0
Age 48 ± 15.1 years
Severe sepsis
Descriptive Young et al., 1997 [65]
Ceftazidime 56.9 ± 25.9 9.1 ± 4.8 4.8 ± 1.9 N =1 5
Age 59.3 ± 14.6 years
Severe sepsis
Descriptive Gómez et al., 1999 [66]
Ceftazidime 22.9 [11.8 to
28.1]
2.8 [0.2 to
7.8]
7.7 [2 to
44.7]
N =2 1
Age range 27 to 73
years
Melioidosis
Not randomized,
parallel, controlled
Angus et al., 2000 [71]
Ceftazidime 25.6 ± 11.2
c 11.0 ± 5.3
c 1.7 ± 0.7
c N =1 4
Age 36.1 ± 12.8 years
Gram-negative
nosocomial pneumonia
Not randomized,
parallel, controlled
Hanes et al., 2000 [70]
Ceftazidime 19.6 [14 to
28]
c, e
5.1 [2.3 to
8.9]
c
4.2 [1.3 to
12.3]
c
N =6
Age 64 years [42 to 87]
Surgical peritonitis
Not randomized,
parallel, controlled
Buijk et al., 2002 [74]
aCl: clearance; NR: not reported; PK: pharmacokinetics; T1/2: half-life; VAP: ventilator-associated pneumonia; Vd: volume of distribution.
bfirst-day PK;
cPK after bolus
dosing;
dPK after 1-g bolus dosing;
efor 70 kg;
fcentral compartment;
gPK after 500-mg bolus dosing. Except where otherwise indicated, data are means, means ±
standard deviations or medians [interquartile ranges].
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a
Antibiotics PD targets Percentage of patients achieving targets References
Meropenem, 1 g tid or 3 g/day CI 40% f T > MIC, with f assumed to
be 98%.
CFR according to Mystic database
PTA for MIC = 2 mg/L: bolus 100%, CI 100% Roberts et al.,
2009 [24]
PTA for MIC = 8 mg/L: bolus 70%, CI 100%
CFR for EC: bolus 100%, CI 100%
CFR for PA: bolus 40.6%, CI 100%
Ceftazidime, 2 g 70% T > 4 × EUCAST breakpoint
of PA
28% Taccone et al.,
2010 [23]
Cefepime, 2 g 70% T > 4 × EUCAST breakpoint
of PA
16%
Meropenem, 1 g 40% T > 4 × EUCAST breakpoint
of PA
75%
Piperacillin/tazobactam, 4.5 g 50% T > 4 × EUCAST breakpoint
of PA
44%
Imipenem 1 g tid or 2 g/day CI 40% f T > MIC, with f assumed to
be 80%
MIC = 2 mg/L bolus dosing 88%, CI 100% Sakka et al., 2007
[31]
MIC = 4 mg/L bolus 75%, CI 86%
Piperacillin/tazobactam 4.5 g qid or 13.5
gC I
50% f T > MIC.
CFR according to Mystic database
PTA for MIC = 0.25 mg/L bolus 79.2%, CI 100% Roberts et al.,
2009 [46]
PTA for MIC = 1 mg/L bolus 60%, CI 100%
CFR for 18 g/day: bolus 53.4%, CI 92.5%
CFR for 13.5 g/day: bolus 40%, CI 92.4%
Cefpirome 2 g bid 60% T > MIC PTA for MIC = 4 mg/L: bolus 60%, CI (4 g/day)
100%
Lipman et al.,
2001 [48]
PTA for MIC = 16 mg/L: bolus 10%, CI (4 g/day)
50%
Cefpirome 2 g tid 60% T > MIC plasma and tissue PTA for MIC = 4 mg/L: plasma 100%, tissue 100% Sauermann et al.,
2005 [51]
PTA for MIC = 16 mg/L: plasma 87.5%, tissue 75%
Cefpirome 2 g bid 65% f T > MIC, with f assumed to
be 90%.
CFR according to EUCAST
database
CFR for EC: bolus 99.9%, CI (4 g/day) 100% Roos et al., 2007
[50]
CFR for PA: bolus 56.1%, CI (4 g/day) 84.4%
Cefepime 2 g 60% T > MIC
MIC = 8 mg/L (NCCLS break point
of PA)
PTA with 1 g bid 45%
PTA with 2 g bid 68%
Bonapace et al.,
1999 [57]
PTA for MIC = 4 mg/L: 1 g bid 68%, 2 g bid 89%
Cefepime 2 g 65% f T > MIC, with f assumed to
be 90%.
CFR according to Queensland
Health Pathology Service
CFR for EC: 2 g bid 78.9%, CI (4 g/day) 96.9% Roos et al., 2006
[60]
CFR for PA: 2 g bid 54%, CI (4 g/day) 91.7%
Ceftazidime 1 g every 4 hours 100% T > 4 × MIC (isolated
pathogens; if negative cultures
100% T > 16 mg/L)
Ceftazidime 47.8%
PTA with 1 g every 3 hours 88.2%
Conil et al., 2007
[54]
Cefepime 2 g tid Cefepime 20%
PTA with 1 g every 4 hours 88.2%
Cefepime 2 g tid 50% f T > MIC, with f assumed to
be 85%
PTA for MIC = 8 mg/L 91.8% Nicasio et al.,
2009 [59]
PTA for MIC = 32 mg/L 50.3%
Cefepime 2 g (each 12 to 36 hours) 50% T > MIC
MIC = 8 mg/L
First dose 67%; steady-state 44% Chapuis et al.,
2010 [55]
Ceftazidime 2 g tid 100% T > 5 × MIC
MIC = 8 mg/L (PA break point)
10% Young et al., 1997
[65]
PTA for CI (6 g/day) 60%
Ceftazidime 2 g tid or 6 g/day CI 100% T > 5 × MIC
MIC = 8 mg/L (PA break point)
Bolus 20% Lipman et al.,
1999 [68]
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Page 8 of 17aeruginosa after bolus dosing, whilst with continuous
infusion they were 100% for both bacteria, despite the
use of a small daily dose (2 g/day) [27].
Imipenem
In ICU patients, increased Vd and Cl of imipenem have
also been reported (Table 1). Therefore, its T1/2 and T >
MIC may be difficult to predict, depending on the rela-
tive changes of these two parameters. This difficulty was
shown by Belzberg et al. [28] in a cohort of ICU surgical
and trauma patients with presumed Gram-negative sep-
sis. In this relatively young population (mean age 45.2 ±
17 years and mean body weight 79.7 ± 17.7 kg), 44% of
patients presented trough levels lower than the intended
4 mg/L at steady state. A mean Cr Cl of 103.8 mL/min-
ute was found, but with large variability: two patients
had renal failure and nineteen patients had a Cr Cl >
Table 2 Pharmacodynamic targets of b?β?-lactam antibiotics
a (Continued)
CI 100%
Ceftazidime 1.5 g tid or 4.5 g/day CI T > 4 × MIC plasma and
peritoneum (isolated pathogens)
Plasma: bolus dosing 100%, CI 100% Buijk et al., 2002
[74]
Peritoneum: bolus 88%, CI 100%
Ceftazidime 2 to 6 g/day CI 100% T > 5 × MIC
MIC = 8 mg/L (PA break point)
Target concentration 40 ± 10 mg/
L
35.9% Aubert et al., 2010
[72]
Percentage of time on target (mean)
Meropenem 2 g tid or 3 g CI T > MIC (isolated susceptible
pathogens)
Bolus T = 100%; CI T = 100% Thalhammer et
al., 1999 [27]
Meropenem 1 g tid T > MIC (isolated pathogens) T = 90.8% de Stoppelaar et
al, 2000 [19]
T > 4 × MIC T = 52%
Meropenem 1 g bid or 1 g tid T > MIC (isolated pathogens) T = 80.9% (Cr Cl > 50 mL/minute; 1 g tid) Kitzes-Cohen et al,
2002 [21]
T = 91.7% (Cr Cl < 50 mL/minute; 1 g bid)
Imipenem 1 g tid T > MIC (isolated sensitive [MIC ≤
2 mg/L] pathogens)
T = 100%; T > 4 × MIC T = 87.5% Novelli et al., 2005
[29]
Meropenem 1 g tid T > MIC (isolated sensitive [MIC ≤
2 mg/L] pathogens)
T = 100%; T > 4 × MIC T = 87.5%
Meropenem 1 g tid (bolus or 3-hour
infusion) or 2 g tid (3-hour infusion)
T > MIC For MIC = 1 mg/L: 1 g tid bolus T = 74.7%, 1 g
tid 3 hours T = 93.6%, 2 g tid 3 hours T = 98.6%s
Jaruratanasirikul et
al., 2005 [20]
For MIC = 16 mg/L: 1 g tid bolus T = 28.3%, 1 g
tid 3 hours T = 37.8%, 2 g tid 3 hours T = 57.9%
Meropenem 1 g tid T > MIC For MIC = 4 mg/L: plasma T = 87%, peritoneum T
= 87%
Karjagin et al.,
2008 [25]
For MIC = 16 mg/L: plasma T = 55%, peritoneum
T = 43%
Imipenem 500 mg qid (30 minutes or
2-hour infusion) or 1 g qid (2-hour
infusion)
T > MIC For MIC = 1 mg/L: 500 mg qid 30 minutes T =
64.7%, 500 mg qid 2 hours T = 76.5%, 1 g qid 2
hours T = 93.4%
Jaruratanasirikul
and Sudsai, 2009
[30]
For MIC = 4 mg/L: 500 mg qid 30 minutes T =
20.3%, 500 mg qid 2 hours T = 17.7%, 1 g qid 2
hours T = 60.3%
Piperacillin 3 g qid or 8 g/day CI T > MIC For MIC = 16 mg/L: bolus dosing T = 62%, CI T =
100%
Rafati et al., 2006
[40]
For MIC = 32 mg/L: bolus T = 39%, CI T = 65%
Cefepime 2 g bid T > MIC
MIC = 7 mg/L (MIC90 of PA)
T = 80% Kieft et al., 1993
[53]
Ceftazidime 2 g tid or 3 g/day CI T > MIC
MIC = 4 mg/L (MIC of one isolated
PA)
Bolus T = 92%; CI T = 100% Benko et al., 1996
[67]
Ceftazidime 2 g tid or 60 mg/kg/day CI T > MIC (isolated pathogens) Bolus T = 92.9%; CI T = 100% Hanes et al., 2000
[70]
aAB: Acinetobacter baumanii; bid: dose every 12 hours; CFR: cumulative fraction of response; CI: continuous infusion; Cr Cl: creatinine clearance; EC: Escherichia coli;
EUCAST: European Committee on Antimicrobial Susceptibility Testing; f: free drug fraction; KP: Klebsiella pneumoniae; MIC: minimal inhibitory concentration; MIC90:
90
th percentileof MIC in a bacteria population; NCCLS: National Committee for Clinical Laboratory Standards; PA: Pseudomonas aeruginosa; PD:
pharmacodynamics; PTA: probability of target attainment; qid: dose every 6 hours; SA: Staphylococcus aureus; T > MIC: time that antibiotic concentration is above
bacteria MIC; tid: dose every 8 hours.
Gonçalves-Pereira and Póvoa Critical Care 2011, 15:R206
http://ccforum.com/content/15/5/R206
Page 9 of 17Table 3 Tissue penetration of b-lactams
a
Antibiotics Samples Patient demographics Concentration ratios
b References
Muscle and subcutaneous tissue
Meropenem Microdialysis in subcutaneous
tissue
N = 10 severe sepsis, 5
continuous infusion
Bolus 0.44
Continuous infusion 0.57 (day 2)
Roberts et al., 2009
[24]
Imipenem Microdialysis in muscle and
subcutaneous tissue
N = 11 (6 patients)
Severe sepsis
Patients Tegeder et al., 2002
[32]
￿ Muscle 0.1
￿ Subcutaneous 0.14
Volunteers
￿ Muscle 0.5
￿ Subcutaneous 0.43
Imipenem Microdialysis in muscle N = 12 (6 patients)
Severe sepsis
Patients 1
Volunteers 0.97
Dahyot et al., 2008
[33]
Piperacillin Microdialysis in muscle and
subcutaneous tissue
N = 12 (6 patients)
Septic shock
Patients Joukhadar et al.,
2001 [44]
￿ Muscle 0.19
￿ Subcutaneous 0.1
Volunteers
￿ Muscle 0.55
￿ Subcutaneous 0.31
Piperacillin Microdialysis in subcutaneous
tissue
N =1 3
Severe sepsis
Bolus 0.21
Continuous infusion 0.2
Roberts et al., 2009
[45]
Cefpirome Microdialysis in muscle N = 18 (12 patients)
Severe sepsis or septic shock
Patients 0.63
Volunteers 0.83
Joukhadar et al.,
2002 [52]
Cefpirome Microdialysis in subcutaneous
tissue
N = 18 (11 patients)
Severe sepsis
Patients 0.43
Volunteers 0.79
Sauermann et al.,
2005 [51]
Burned skin
Cefepime Biopsy of burned area N =6
Burn patients
Day 3 1.52 (point concentration 3 to 5
hours after dose)
Sampol et al., 2000
[61]
Peritoneum
Meropenem Microdialysis in peritoneum N =6
Surgical peritonitis
0.74 Karjagin et al., 2008
[25]
Ceftazidime Peritoneal drainage N =1 8
Surgical peritonitis
Day 2
￿ Continuous infusion 0.56
Buijk et al., 2002 [74]
￿ Bolus 0.35
Imipenem ELF (bronchoscopy) N =8
Pneumonia
0.20 (point concentration ratio 2 hours
after dose)
Muller-Serieys et al.,
1987 [35]
Imipenem Bronchial secretions (tracheal
aspirate)
N =1 0
Trauma patients with VAP
NR McKindley et al.,
1996 [34]
Piperacillin ELF (bronchoscopy) N =1 0
VAP
0.57 (point concentration ratio 5 hours
after dose)
Boselli et al., 2004
[41]
Piperacillin ELF (bronchoscopy) N =4 0
VAP
0.44 (point concentration ratio 4 hours
after dose)
Boselli et al., 2008
[43]
Piperacillin Bronchial secretions (tracheal
aspirate)
N =8
VAP
0.36 Jehl et al., 1994 [42]
Cefepime ELF (bronchoscopy) N =2 0
VAP
1.04 (point concentration ratio) Boselli et al., 2003
[63]
Cefepime or
ceftazidime
Bronchial secretions (tracheal
aspirate)
N = 5 cefepime
VAP
Cefepime < 0.02 Klekner et al., 2006
[62]
N = 4 ceftazidime
VAP
Ceftazidime < 0.05
Ceftazidime Bronchial secretions (tracheal
aspirate)
N =5
Pneumonia
0.12 Langer et al., 1991
[76]
Ceftazidime Bronchial secretions (tracheal
aspirate)
N =1 2
Nosocomial pneumonia
0.76 Bressolle et al., 1992
[77]
Ceftazidime ELF (bronchoscopy) N =1 5
VAP
0.21 (point concentration ratio at
steady state)
Boselli et al., 2004
[69]
aELF: epithelial lining fluid; NR: not reported.
bMean area under the concentration time curve (AUC) tissue-to-plasma ratio unless otherwise stated.
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between PK parameters and body weight, severity of dis-
ease, blood pressure or renal function [28].
Another study compared meropenem and imipenem
first-dose PK in patients with normal renal function
(serum Cr < 1.5 mg/dL). Again, both Vd and Cl were
significantly elevated, although more so in the merope-
nem group [29]. However, their T > MIC for sensitive
isolated pathogens were similar. Again, there was a rela-
tionship between Cr Cl and T1/2: Patients with a Cr Cl
< 50 mL/minute had a significantly longer T1/2 for both
antibiotics.
The PD efficacy of imipenem is also influenced by the
dose and the time of infusion [30]. Using PK data from a
cross-over steady-state study of VAP patients, Jaruratana-
sirikul and Sudsai [30] showed by modelling of imipenem
PD that, for a MIC of 4 mg/L, a 500-mg dose delivered
every 6 hours (qid) for 30 minutes achieved a T > MIC of
64.7% and increased to 76.5% with a 2-hour infusion.
However, this study excluded shock and renal failure
patients (Cr Cl < 60 mL/minute). With PD modelling of
PK data derived from another 20 VAP patients [31], con-
tinuous infusion led to improved PTA despite the use of
lower dosages (Table 2). In this latter study, all patients
had f imipenem T > MIC of 100%, but three patients died.
Tissue microdialysis had been used to assess imipe-
nem PK, but with very dissimilar results (Table 3):
namely, the tissue-to-plasma ratio. This has been found
to be markedly depressed in a cohort of severe critically
ill patients compared to healthy volunteers (subcuta-
neous tissue-to-plasma 0.14 vs. 0.43 and muscle tissue-
to-plasma 0.11 vs. 0.5, respectively) [32]. However,
Dahyot et al. [33] disputed these results and found f
imipenem in plasma and muscle to be virtually superim-
posed at any time, both in patients and in healthy
volunteers. Some differences exist between these two
studies. In the Tegeder et al. study [32], the patients
had lower Cr Cl (medians 32.8 mL/minute vs. 156 mL/
minute) and samples were collected at steady state and
not after the first dose. Moreover, Dahyot et al. [33]
accounted only for the f imipenem in plasma and found
higher imipenem Vd and Cl. Different methods of calcu-
lating in vivo microdialysis recovery rates may also
explain some of the diverse observed results. Neverthe-
less, low imipenem penetration ratios, as low as 0.06
[34,35], in bronchial secretions were reported in pneu-
monia patients (Table 3).
Penicillins
Piperacillin
Similarly to other b-lactams, piperacillin Vd and Cl have
generally been found to be increased in ICU patients
(Table 1). However, most studies have excluded renal
failure patients.
Piperacillin Cl and trough concentrations were
strongly related to Cr Cl [36-38]. Taccone et al.[ 2 3 ]
s h o w e dt h a to n l y1 5 %o fp a t i e n t sw i t hh i g hC rC l( >5 0
mL/minute) maintained piperacillin concentrations >
50% of T > 4 × MIC after the first antibiotic dose, as
opposed to 71% of patients with lower Cr Cl (P =0 . 0 3 ) .
In contrast, in 10 young burn patients (mean total
burned area 40.8 ± 3.1%) with a mean Cr Cl of 119.8
mL/minute and Pseudomonas aeruginosa infection, the
authors found a 20% increase in T1/2 after the first dose
of antibiotic compared to the third day of therapy,
which was related to a larger Vd (mean of 19.6 L vs.
16.4 L) [38]. Overall, the piperacillin AUC was similar in
the two measurements (mean of 640 mg × hour/L vs.
622 mg × hour/L).
Piperacillin is stable for at least 24 hours at room tem-
perature, making it a suitable choice for continuous
infusion. With this strategy, higher steady-state concen-
trations are expected, theoretically providing a higher T
> MIC even with the use of a lower daily dose [39]. A
s t u d yb yR a f a t iet al.[ 4 0 ]a l s os u p p o r t st h i ss t r a t e g y .
These authors showed that, for a MIC = 16 mg/L, the T
> MIC was higher with continuous infusions (8 g/day)
than with bolus dosing (3 g tid) (100% vs. 62%, respec-
tively). However, the mortality rate was similar.
In VAP patients, piperacillin showed good penetration
in bronchial secretions [41-43]. Nevertheless, its epithe-
lial lining fluid (ELF) steady-state concentration was
lower than the MIC for Pseudomonas aeruginosa after a
4.5-g tid dose [41]. With continuous infusion, an
increase in pulmonary concentration was found, at least
in the subset of patients with moderate renal failure
(measured Cr Cl < 50 mL/minute), about three times
higher than in the patients with normal renal function
[43]. However, no relationship was found between ELF
piperacillin concentration and clinical success. Similar
concentrations were found in the eight patients who
died or had persistent infections and in those who
experienced therapeutic success [43].
Subcutaneous tissue-to-plasma ratio and PK have been
assessed in microdialysis studies. In six septic shock
patients (mean norepinephrine dose 0.8 μg/kg/minute)
[44], the subcutaneous tissue-to-plasma AUC ratio was
only 0.1, one-third of that measured in healthy volun-
teers. Peak tissue concentration was also delayed in
patients (122 minutes in patients compared with 27
minutes in healthy volunteers), and T1/2 in tissues was
nearly nine times longer. In 13 younger patients with
less severe sepsis [45], the AUC tissue-to-plasma ratio
was roughly 0.2. In accordance with their serum PK (as
well as PK of another five patients) [46], piperacillin/
tazobactam CFR was calculated to be 92.3% with contin-
uous infusion (13.5 g/day) and 53.4% with bolus dosing
(4.5 g qid, or 18 g/day). Again, no correlation was found
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low tissue concentration levels, all patients in both
groups survived [45].
Cephalosporins
Cefpirome
Cefpirome PK studies have produced heterogeneous
results. A 2-g dose was adequate in young trauma
patients (Cr Cl ≥ 50 mL/minute) and in similar
healthy volunteers. After the first dose, the mean T >
MIC were 75% and 80%, respectively (with a MIC of 4
mg/L, P = 0.76) [47]. However, in 12 similar patients,
a lower T > MIC (60%) was found, which was prob-
ably related to higher cefpirome Cl [48]. After four
days of therapy, the cefpirome mean PK parameters
remained similar (T > MIC 67% and AUC 242 mg ×
hour/L vs. 306 mg × hour/L at steady state). Further
analyses [49] showed a strong correlation between Cr
Cl and either cefpirome or cefepime Cl (r
2 =0 . 8 1 ) .
Patients with the lower range of T > MIC had a
higher Cr Cl, usually above 144 mL/minute [49].
According to these measured PK data, the authors
performed a simulation to demonstrate improved CFR
of cefpirome given as a continuous infusion to treat
Pseudomonas aeruginosa infection, from 56.1% to
84.4% (Table 2) [50].
C e f p i r o m et i s s u eP Kw e r ee v a l u a t e do nt h eb a s i so f
microdialysis. Sauermann et al. [51] found a low subcu-
taneous tissue concentration in patients with severe sep-
sis, almost half of healthy volunteers, despite a longer
plasma T1/2 (183 minutes vs. 95 minutes; P <0 . 0 5 ) .
Similar results were reported by Joukhadar et al.[ 5 2 ] ,
who found muscle-to-plasma ratios of 0.63 in patients
and 0.83 in healthy volunteers (Table 3).
Cefepime
Roughly a twofold variation of cefepime Vd has been
reported in PK studies (Table 1) of severe sepsis and
septic shock patients [23], elderly septic patients [53],
young burn patients [54] and nosocomial pneumonia
patients [55]. Cefepime Cl has also been found to be
closely correlated with Cr Cl in this last listed cohort (r
2
= 0.77) [55], in another cohort of septic patients (r
2 =
0.74) [56] and in burn patients (r
2 = 0.58) [57]. There-
fore, patients with renal dysfunction may experience
toxicity.
In 21 septic patients receiving cefepime at a dose of 2
g bid, more than twofold peak variations and roughly
40-fold trough variations were observed. Again, the cefe-
pime Cl correlated with Cr Cl (r
2 = 0.77). Two patients
with low Cr Cl (19 and 12 mL/minute) had trough
levels > 20 mg/L despite dosage adjustment. They both
had neurologic symptoms (namely, confusion and mus-
cle jerks) that were not identified as toxicity but
resolved promptly after drug arrest [55].
A cefepime bolus of 2 g bid was found to be insuffi-
cient to reach a high PD target after the first dose
(Table 2), both in 80% of young burn patients (burn
area 21.8%) with high mean Cr Cl (119.2 mL/minute)
[54] and in the Taccone et al. study [23], in which only
16% of patients achieved the intended target.
Two other studies have evaluated cefepime PK, one of
which addressed the first day of therapy for 55 nosoco-
mial pneumonia or bacteraemia patients (67% trauma)
[58] and the other of which described the status of 32
VAP patients on the second day of cefepime treatment
[59]. Both studies unveiled a relationship between Vd
and total body weight as well as between excretion,
either elimination rate constant [59] or Cl [58], and Cr
Cl. However, significant interpatient variability was
again observed, with regard to both cefepime Cl (58%)
and central compartment Vd (67%) [58].
A PD model was developed with this VAP population
PK data: despite a 2-g tid dose, PTA > 90% was
achieved only with a MIC ≤ 8 mg/L [59]. In another
cefepime PD model, the CFR of a 2-g bid dose, used to
treat both Escherichia coli and Klebsiella pneumoniae,
was 78.9%. However, for Pseudomonas aeruginosa,C F R
was only 53.6% (Table 2) and increased with either 2 g
tid or continuous infusion (4 g/day or 6 g/day) to 84.9%,
91.7% and 94.8% respectively. Nevertheless, the CFR for
Acinetobacter baumanii [60], even with a continuous
infusion of 6 g/day, was only 75%, reemphasizing the
importance of appropriate dosing and the potential ben-
efit of continuous infusion against difficult-to-treat
bacteria.
Also, the cefepime tissue concentration was assessed
in biopsy samples collected from the skin of burn
patients three to five hours after a bolus dose on day 3
of antibiotic therapy. A mean biopsy-to-plasma cefepime
ratio of 1.5 (range 0.4 to 5.1) was found [61]. Klekner et
al. [62] were unable to detect cefepime in bronchial
secretions from any of the five studied patients six
hours after an 80 mg/kg dose. However, using continu-
ous infusion (4 g/day) to treat VAP patients, Boselli et
al. [63] found, at steady state, higher and similar plasma
and ELF concentrations (mean of 13.5 mg/L and 14.1
mg/L, respectively). Although different sampling meth-
ods may have influenced these differences, continuous
infusion seems to prolong T > MIC in the lungs. Never-
theless, no correlation with therapeutic outcomes was
reported.
Ceftazidime
Several studies have shown ceftazidime PK heterogeneity
in ICU septic patients with Pseudomonas infections
(mostly nosocomial pneumonia) [64], severe sepsis
[65,66] and burns [54]. Similarly to other b-lactams, the
authors noted a large variation of both Vd and Cl (Table
1) and consequently significant interpatient variability in
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between Cl and Cr Cl was usually reported [65,66].
Continuous infusion of ceftazidime was compared
with bolus dosing in five different studies [67-71]. In all,
there was an increase in T > MIC with continuous infu-
sion despite lower daily doses. However, only in severe
melioidosis was this strategy associated with lower mor-
tality (3 of 10 patients vs. 9 of 11 patients) [71]. Those
patients had low Cr Cl (26.6 mL/minute) and received
ceftazidime dosages adjusted to their body weight (4
mg/kg/hour or 40 mg/kg tid, for a mean body weight of
49.4 kg). Ceftazidime steady-state concentration was
measured in another cohort of 92 patients receiving
continuous infusions [72]. Therapeutic drug monitoring
was performed on the second day of therapy. The mean
serum concentration was 46.9 mg/L, but again with a
very wide range of serum concentrations (7.4 to 162.3
mg/L). Therefore, dosage modification was common
because of low serum levels (36.9%) and high serum
levels (27.2%), with the latter being associated with
lower Cr Cl (mean of 51 mL/minute compared with 103
mL/minute for patients with low serum levels). Similar
results were shown in another large ceftazidime PK
study assessing a mixed septic population with a higher
mean Cr Cl (123 mL/minute) [73]. The lower T > MIC
was found in patients with the higher Cr Cl, especially
after bolus dosing (Table 2).
Continuous infusion of ceftazidime (4.5 g/day) was
also associated with a higher peritoneal AUC at day 2
compared to bolus dosing (1.5 g tid) in surgical patients
with peritonitis (522 mg × hour/L vs. 316 mg × hour/L;
P = 0.01) [74], despite similar serum AUC (and Cr Cl >
30 mL/minute). Therefore, although serum T > 4 ×
MIC was > 90% in all patients, peritoneal T > 4 × MIC
was still > 90% with continuous infusion but only 44%
with bolus dosing. Nevertheless, no difference in mortal-
ity was noted (25% vs. 33%; P = 1.0). A PD model of
ceftazidime in ICU patients also showed higher PTA
with continuous infusion (100% for MIC ≤ 8m g / L )
than with bolus dosing [75].
Ceftazidime concentration in bronchial secretions was
measured in four studies of VAP patients. Very low con-
centrations, < 0.5 mg/L and < 0.3 mg/L, were found in
two of them [62,76]. Bressole et al. [77] found a higher
ratio between bronchial secretions and plasma concen-
tration (0.76) in patients infected after abdominal sur-
gery. A longer T1/2 (6.1 hours) and a lower Cl (4.2 L/
hour) may explain some of these differences. With con-
tinuous infusion, a ratio of 0.21 between ELF and serum
was observed [69].
Discussion
In our systematic review, we have aggregated informa-
tion from 57 prospective studies related to the PK of b-
lactam antibiotics, which are among the most often
agents used to treat sepsis in ICU patients [78]. Overall,
an increased Vd of all the studied antibiotics was
reported (Figure 3), which was related to total body
weight [58,73], but with significant variability. Drug Cl
was also increased and usually related to Cr Cl. Those
changes were largely unpredictable, with important
interpatient variability. However, the higher Cl values
were noted in studies that excluded patients with renal
dysfunction, a common strategy, which may limit the
interpretation of the data reported.
Therapeutic drug monitoring was rarely performed.
In addition, data on the daily variation of PK para-
meters in ICU patients, as well as the ideal frequency
of this monitoring, are currently limited. Nevertheless,
two of the reviewed studies [55,72] showed that inade-
quate dosing may be common in this population and
may jeopardize b-lactam antibiotics efficacy or even
lead to toxicity [79]. Roberts et al.[ 8 0 ]m e a s u r e d
piperacillin/tazobactam concentrations and found that
50.4% of patients first measurement were low. The
clinical efficacy of using drug levels to achieve ade-
quate concentrations had never been properly evalu-
ated. In a recent study, PD modelling was used to
empirically treat 94 VAP in critically ill patients at
high risk of infection with antibiotic-resistant Pseudo-
monas aeruginosa [81]. A three-hour infusion regimen
of either cefepime or meropenem at a high dosage (2 g
tid) was initiated, followed by both antibiotic and dose
de-escalation whenever bacteria with a low MIC were
identified. The infection-related mortality decreased
from 21.6% to 8.5% (P = 0.029).
The PD targets of b-lactam antibiotics may be differ-
ent in patients with severe bacterial infections. McKin-
non et al. [82] evaluated ceftazidime and cefepime PD
by using PK data from previous clinical trials [83].
Maintaining a T > MIC as high as 100% was associated
with a significantly greater clinical cure and bacteriolo-
gic eradication than a shorter time (cefatzidime: 82% vs.
33%, P = 0.002; cefepime: 97% vs. 44%, P = 0.001). Also,
in a febrile neutropenia population of 60 patients treated
with meropenem, a calculated T > MIC of 83% was
found in responders, whilst those with a poor clinical
response had a T > MIC of only 60% [84]. It has also
been suggested that, at least in vivo, maximum killing of
bacteria is achieved at higher concentrations, four to
five times MIC [85], accounting for antibiotic penetra-
tion in infected tissues. As such, concentrations of b-lac-
tam antibiotics may need to be maintained well above
the MIC for extended periods, especially in patients
with life-threatening infections. Accordingly, different
PD targets have been proposed in the different studies
addressing ICU patients, which sometimes make their
comparison difficult.
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by promoting a longer exposure with more frequent
dosing, extended infusions or continuous infusions
[86,87]. Several of the studies that we reviewed reported
PD benefits of continuous infusions (even using small
daily doses) (Table 2). Also, PD modelling tends to sup-
port this strategy. Nevertheless, almost none of the stu-
dies addressed reported a decrease in mortality. In
addition, a recently published meta-analysis of 14 pro-
spective studies did not show a significant benefit of
using this strategy (odds ratio 1.00, 95% confidence
interval 0.48 to 2.06; P = 1.00) [88].
An increasing number of studies have addressed b-lac-
tam antibiotic tissue concentration. Despite the theoreti-
cal advantage of analysing the drug concentration at the
site of infection, there are no data to support a relation-
ship between these concentrations and outcomes.
Furthermore, there are still controversial issues involved
in interpreting these data, namely, microdialysis [32,33].
Therefore, we think that, at present, no recommenda-
tion can be made regarding antibiotic tissue PK.
Conclusions
The PK of b-lactam antibiotics are significantly changed
in septic ICU patients. Dosage and schedule regimens
based on data from healthy volunteers may be mislead-
ing. Therapeutic drug monitoring and PD modelling
according to measured PK previously showed promising
results. Continuous infusion, although theoretically use-
ful, has not been shown to lead to improved outcomes.
The clinical significance of tissue PK monitoring
remains to be determined.
Key messages
￿ Among ICU patients, the PK of b-lactam antibio-
tics are markedly unpredictable.
￿ A large volume of distribution is commonly
observed in ICU patients and contributes to a lower
antibiotic concentration, but also to a greater expo-
sure time.
￿ An increased glomerular filtration rate is usually
associated with a short half-life of b-lactam antibio-
tics, whilst renal failure is associated with a greater
exposure and increased risk of accumulation.
￿ Continuous infusion of b-lactam antibiotics com-
monly increases the time that the antibiotic concen-
tration exceeds its MIC and may therefore increase
efficacy.
￿ Therapeutic drug monitoring of b-lactam antibiotic
concentration may help to improve its efficacy and
prevent toxicity, but currently is unavailable in most
clinical settings.
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